It doesnt exclude a whole lot of patients, remembering that the prevalence of medullary thyroid cancer and MEN 2 in the general adult population is somewhere between 1 in 30,000 and 1 in 40,000. Pearce adds that patients and doctors alike should not be unduly concerned by any possible effects on the thyroid
Lose 15% of your body weight with GLP-1s * Lose 15% of your body weight with GLP-1s * *In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, the treatment group receiving semaglutide experienced a mean body weight loss of 15%, compared to 2% of the placebo group
Search Strategy A comprehensive literature search was independently conducted by two reviewers across five major electronic databases - PubMed, Scopus, Web of Science, ScienceDirect, and the Cochrane Library - to identify eligible RCTs evaluating weight loss, weight regain, and rebound effects associated with anti-obesity pharmacotherapies
Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A (2022) GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
